Related Experiment Video
Updated: Jul 13, 2026
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Expression of MAC30 in rectal cancers with or without preoperative radiotherapy
Zhi-Yong Zhang1, Zeng-Ren Zhao, Gunnar Adell
1Department of Oncology, Institute of Biomedicine and Surgery, Linkoping University, Linkoping, Sweden.
Objective:
Meningioma-associated protein (MAC30) is overexpressed in several types of cancers, but its therapeutic implication in the patients has not been studied. We examined the relationship of MAC30 with clinicopathological and biological factors in rectal cancer patients with or without radiotherapy (RT).
Methods:
MAC30 was immunohistochemically examined in 75 distant and 91 adjacent normal mucosa specimens, 132 primary tumours and 39 lymph node metastases from rectal cancer patients participating in a clinical trial of preoperative RT.
Results:
In the RT group, MAC30 was or tended to be positively correlated with infiltrated growth pattern (p = 0.02), PRL (phosphatase of regenerating liver, p = 0.01) and Ki-67 expression (p = 0.06). MAC30 at the invasive margin of the metastasis was related to poor survival (p = 0.02) in the whole group of patients. MAC30 in primary tumours was not related to recurrence and survival in the non-RT or RT group.
Conclusions:
MAC30 expression in metastasis was an indicator for poor survival. After RT, MAC30 seemed to be more related to aggressive morphological and biological factors; however, we did not find direct evidence that MAC30 expression was related to the outcome of patients with or without RT.
Insights
Meningioma-associated protein (MAC30) expression in rectal cancer metastasis indicates poor survival. While MAC30 correlates with aggressive factors after radiotherapy, its direct impact on patient outcomes with or without RT requires further investigation.
Area of Science:
- Oncology
- Cancer Biology
- Molecular Pathology
Background:
- Meningioma-associated protein (MAC30) is overexpressed in various cancers.
- Its therapeutic significance in patients remains largely unstudied.
- Rectal cancer treatment often involves radiotherapy (RT).
Purpose of the Study:
- To investigate the relationship between MAC30 expression and clinicopathological/biological factors in rectal cancer patients.
- To assess MAC30's correlation with outcomes in patients who received preoperative radiotherapy (RT) versus those who did not.
Main Methods:
- Immunohistochemistry was used to examine MAC30 expression.
- Specimens included normal mucosa, primary tumors, and lymph node metastases from 132 rectal cancer patients.
- Patients were part of a clinical trial involving preoperative RT.
Main Results:
- In the RT group, MAC30 correlated with infiltrated growth pattern (p=0.02) and PRL (p=0.01).
- MAC30 at the invasive margin of metastasis predicted poor survival (p=0.02) across all patients.
- MAC30 in primary tumors did not correlate with recurrence or survival, irrespective of RT.
Conclusions:
- MAC30 expression in metastasis serves as a prognostic indicator for poor survival.
- Post-RT, MAC30 appears associated with more aggressive tumor characteristics.
- No direct evidence was found linking MAC30 expression to patient outcomes in the context of RT.